BBA
PTGX icon

Baker Bros. Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Baker Bros. Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-455,276
Closed -$20.4M – 127
2021
Q2 		$20.4M Sell
455,276
-980,916
-68% -$32.4M 0.09% 63
2021
Q1 		$37.2M Hold
1,436,192
– – 0.16% 50
2020
Q4 		$29M Sell
1,436,192
-160,006
-10% -$3.44M 0.11% 47
2020
Q3 		$31.2M Sell
1,596,198
-315,248
-16% -$5.92M 0.12% 41
2020
Q2 		$33.8M Buy
1,911,446
+232,282
+14% +$2.91M 0.15% 39
2020
Q1 		$11.9M Buy
1,679,164
+504,882
+43% +$3.78M 0.07% 48
2019
Q4 		$8.28M Hold
1,174,282
– – 0.04% 58
2019
Q3 		$14.1M Buy
1,174,282
+179,200
+18% +$2.26M 0.1% 46
2019
Q2 		$12.1M Buy
995,082
+591,189
+146% +$6.54M 0.08% 47
2019
Q1 		$5.08M Buy
+403,893
New +$3.57M 0.03% 60

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Baker Bros. Advisors's PTGX Position: Q3 2021 in Review

Baker Bros. Advisors sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 455,276 shares — an estimated $20.4M sold.

Baker Bros. Advisors first reported a position in PTGX in Q1 2019 and held it in 10 quarters. The position peaked at $37.2M in Q1 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

  • Baker Bros. Advisors reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Baker Bros. Advisors sold 455,276 Protagonist Therapeutics shares in Q3 2021, an estimated $20.4M.
  • Baker Bros. Advisors first reported a position in Protagonist Therapeutics in Q1 2019 and held it in 10 quarters.
  • Baker Bros. Advisors's Protagonist Therapeutics position peaked at $37.2M in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.